A First-In-Human, Phase 1, Dose-Escalation Study of SGR-3515 In Participants with Advanced Solid Tumors

Disease Sites:

Not Available

Staging:

Phase I

Age Group:

Adults

Therapies:

Mol. targeted/Immunotherapy/Biologics

Drugs:

Not Available

Principal Investigator(s):

Gibson, Mike

Scope:

International

Participating Institutions:

Vanderbilt University

Open Date:

03-17-2025

Trial Type:

Treatment

Protocol ID:

VICC-DTPHI24100

National Clinical Trial ID:

NCT06463340

Eligibility

Ages Eligible for Study:

Not Available

Genders Eligible for Study:

Not Available

Accepts Healthy Volunteers?:

Not Available